Alcohol Consumption Before and After Breast Cancer Diagnosis: Associations With Survival From Breast Cancer, Cardiovascular Disease, and Other Causes

Purpose Alcohol intake is associated with increased risk of breast cancer. In contrast, the relation between alcohol consumption and breast cancer survival is less clear. Patients and Methods We assessed pre- and postdiagnostic alcohol intake in a cohort of 22,890 women with incident invasive breast cancer who were residents of Wisconsin, Massachusetts, or New Hampshire and diagnosed from 198 to 200 at ages 20 to 79 years. All women reported on prediagnostic intake; a subsample of 4,881 reported on postdiagnostic intake. Results During a median follow-up of 11.3 years from diagnosis, 7,780 deaths occurred, including 3,484 resulting from breast cancer. Hazard ratios (HR) and 95% CIs were estimated. Based on a quadratic analysis, moderate alcohol consumption before diagnosis was modestly associated with disease-specific survival (compared with nondrinkers, HR = 0.93 [95% CI, 0.85 to 1.02], 0.85 [95% CI, 0.75 to 0.95], 0.88 [95% CI, 0.75 to 1.02], and 0.89 [95% CI, 0.77 to 1.04] for two or more, three to six, seven to nine, and ≥ 10 drinks/wk, respectively). Alcohol consumption after diagnosis was not associated with disease-specific survival (compared with nondrinkers, HR = 0.88 [95% CI, 0.61 to 1.27], 0.80 [95% CI, 0.49 to 1.32], 1.01 [95% CI, 0.55 to 1.87], and 0.83 [95% CI, 0.45 to 1.54] for two or more, three to six, seven to nine, and ≥ 10 drinks/wk, respectively). Results did not vary by beverage type. Women consuming moderate levels of alcohol, either before or after diagnosis, experienced better cardiovascular and overall survival than nondrinkers. Conclusion Overall alcohol consumption before diagnosis was not associated with disease-specific survival, but we found a suggestion favoring moderate consumption. There was no evidence for an association with postdiagnosis alcohol intake and breast cancer survival. This study, however, does provide support for a benefit of limited alcohol intake for cardiovascular and overall survival in women with breast cancer.

Download Full-text

25-Hydroxyvitamin D at time of breast cancer diagnosis and breast cancer survival

Breast Cancer Research and Treatment ◽

10.1007/s10549-019-05486-4 ◽

2019 ◽

Vol 179 (3) ◽

pp. 699-708 ◽

Cited By ~ 2

Author(s):

Charlotte Kanstrup ◽

Dorthe Teilum ◽

Lars Rejnmark ◽

Janne Villemoes Bigaard ◽

Pia Eiken ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Diagnosis ◽

Cancer Survival ◽

Breast Cancer Diagnosis ◽

Breast Cancer Survival ◽

Hydroxyvitamin D ◽

25 Hydroxyvitamin D

Download Full-text

Clinical outcomes in very early breast cancer (≤ 1cm): A national population based analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2017.35.15_suppl.e12034 ◽

2017 ◽

Vol 35 (15_suppl) ◽

pp. e12034-e12034

Author(s):

Mahvish Muzaffar ◽

Abdul Rafeh Naqash ◽

Nasreen A. Vohra ◽

Darla K. Liles ◽

Jan H. Wong

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Early Breast Cancer ◽

Older Age ◽

National Database ◽

Disease Specific Survival ◽

Excellent Outcome ◽

Significant Difference ◽

Er Positive ◽

Disease Specific

e12034 Background: The utilization of screening mammogram has resulted in increased diagnosis of very small breast cancers including T1a (≤5 mm), T1b ( > 0.5 but ≤1 cm). These small tumors have excellent prognosis with cancer-specific survival rates as high as 90% to 95%.This study evaluates outcomes in very early breast cancer in a national database. Methods: Patients with stage I breast cancer, tumor ≤ 1cm (T1aN0, T1bN0) diagnosed between 2006 and 2011 were selected from the SEER database. We excluded patients with missing biomarker information. Treatment outcome and prognostic factors for disease-specific survival (DSS) and overall survival (OS) were evaluated. Results: We identified 70,543 cases and included 54,796 patients with stageT1aN0M0 and T1bN0M0 in the final analysis.The mean age was 62.09 yrs(CI 95% 62.2-61.99),84% are white,7% black and 7% Other.89% were ER positive,11% ER negative and 3% had Her 2 positive tumors.71% of patients had T1b. ≤ 1cm breast cancer cases increased from 15% in 2006 to 18% in 2011.The 5-year disease specific survival (DSS) and overall survival (OS) for patients with stage T1aN0T1b N0 was 98.7% and 93.7%, respectively. Estrogen receptor(ER) positive tumors were associated with improved 5-yr DSS 99% vs 96% in ER negative (p < 0.0001) and OS in ER positive 94% vs 92%( p < 0.0001).Among white patients 5-yr DSS was 98.8% and OS was 93.7% while 5yr-DSS was 94%,OS 91.5% among black vs 5-yr DSS 99% and OS 96.3% in others( Asian or Pacific Islanders,AI), (p < 0.0001).Tumor subtype was not associated with significant difference in outcome but T1a tumor was associated with OS 94.5% vs 93.4% with T1b tumors(p < 0.0001) On cox model analysis factors which correlated with prolonged DSS and OS are race (p < 0.0001),older age (p < 0.0001), ER positivity (p < 0.0001) and tumor less than 5mm (p = 0.0006). Conclusions: Very early breast cancer is associated with excellent outcome but has some heterogeneity. Nonwhite/Non Black race was associated with better survival compared to white and black patients.ER positive tumors, older age were also associated with better outcome. This data while reassuring also brings into question of overtreatment of this disease subset.

Download Full-text

Alcohol intake over the life course and breast cancer survival in Western New York exposures and breast cancer (WEB) study: quantity and intensity of intake

Breast Cancer Research and Treatment ◽

10.1007/s10549-013-2533-y ◽

2013 ◽

Vol 139 (1) ◽

pp. 245-253 ◽

Cited By ~ 7

Author(s):

Anne M. Weaver ◽

Susan E. McCann ◽

Jing Nie ◽

Stephen B. Edge ◽

Thomas H. Nochajski ◽

...

Keyword(s):

Breast Cancer ◽

New York ◽

Life Course ◽

Alcohol Intake ◽

Cancer Survival ◽

Breast Cancer Survival ◽

The Life Course

Download Full-text

Pre-diagnostic alcohol consumption and postmenopausal breast cancer survival: a prospective patient cohort study

Breast Cancer Research and Treatment ◽

10.1007/s10549-012-2230-2 ◽

2012 ◽

Vol 136 (1) ◽

pp. 195-207 ◽

Cited By ~ 20

Author(s):

Alina Vrieling ◽

Katharina Buck ◽

Judith Heinz ◽

Nadia Obi ◽

Axel Benner ◽

...

Keyword(s):

Breast Cancer ◽

Cohort Study ◽

Alcohol Consumption ◽

Cancer Survival ◽

Postmenopausal Breast Cancer ◽

Breast Cancer Survival ◽

Patient Cohort

Download Full-text

Killing time: Treatment delay and breast cancer survival

Journal of Clinical Oncology ◽

10.1200/jco.2007.25.18_suppl.6589 ◽

2007 ◽

Vol 25 (18_suppl) ◽

pp. 6589-6589

Author(s):

S. Sheinfeld Gorin ◽

J. E. Heck ◽

B. Cheng

Keyword(s):

Breast Cancer ◽

Cancer Treatment ◽

Propensity Scores ◽

Cancer Survival ◽

Treatment Delay ◽

Breast Cancer Treatment ◽

Breast Cancer Survival ◽

Access To Treatment ◽

Breast Cancer Death ◽

Increased Risk

6589 Introduction: Treatment delay is commonly associated with reduced breast cancer survival. Inadequate or delayed follow-up for positive findings is the most common reason for breast cancer-related litigation in the U.S. The United Kingdom has made improvements in the delivery of breast cancer services a priority for resources with the aim of reducing delays. Yet, the evidence for the association of delay and breast cancer survival is mixed. Most studies rely on small, non-representative cohorts, treatment approaches have changed over the time since the the most widely-cited review. Studies cite wide variations in delay, and some research is subject to publication or lead time bias. Aims. The purpose of this study is to examine the influence of 3-month breast cancer treatment delay on survival using a large, longitudinal, population-based dataset to provide more definitive findings. Methods: Subjects were 43,359 female Medicare enrollees age 65 and older who were diagnosed with breast cancer between 1992 and 1999 and identified by the Surveillance, Epidemiology, and End Results (SEER) program for whom treatment delay information could be obtained. Billing claims from inpatient, outpatient and provider visits were used. Mortality from breast cancer was assessed through SEER linkage with death certificates. Using propensity scores to balance the comparison groups, the association between treatment delays of three months or more and cancer survival time were analyzed using Cox proportional hazards models with gamma frailty to account for the clustering effect due to census tract. To account for known predictors of breast cancer survival, in addition to the propensity scores, we adjusted for cancer stage, comorbidity, marital status, tumor characteristics, location, detection by screening or diagnostic mammography, and the average number of health provider visits during the study period. Results: Subjects who had over a three month delay in receiving any treatment had a 34% increased risk of breast cancer death by comparison to women with delays less than three months (adjusted Hazard ratio 1.34, 1.01–1.77). Discussion: Three-month delays in accessing breast cancer treatment have a clear relationship to survival. Rapid access to treatment is recommended for all women with breast cancer. No significant financial relationships to disclose.

Download Full-text

Ginseng and Ganoderma lucidum Use after Breast Cancer Diagnosis and Quality of Life: A Report from the Shanghai Breast Cancer Survival Study

PLoS ONE ◽

10.1371/journal.pone.0039343 ◽

2012 ◽

Vol 7 (6) ◽

pp. e39343 ◽

Cited By ~ 21

Author(s):

Ping-Ping Bao ◽

Wei Lu ◽

Yong Cui ◽

Ying Zheng ◽

Kai Gu ◽

...

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Cancer Diagnosis ◽

Ganoderma Lucidum ◽

Cancer Survival ◽

Breast Cancer Diagnosis ◽

Breast Cancer Survival ◽

Survival Study

Download Full-text

Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis

Scientific Reports ◽

10.1038/s41598-021-99409-3 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Maria Escala-Garcia ◽

Sander Canisius ◽

Renske Keeman ◽

Jonathan Beesley ◽

Hoda Anton-Culver ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Diagnosis ◽

Primary Breast Cancer ◽

Cancer Survival ◽

Distant Metastases ◽

Breast Cancer Diagnosis ◽

Breast Cancer Survival ◽

European Ancestry ◽

Validation Dataset ◽

Germline Variants

AbstractBreast cancer metastasis accounts for most of the deaths from breast cancer. Identification of germline variants associated with survival in aggressive types of breast cancer may inform understanding of breast cancer progression and assist treatment. In this analysis, we studied the associations between germline variants and breast cancer survival for patients with distant metastases at primary breast cancer diagnosis. We used data from the Breast Cancer Association Consortium (BCAC) including 1062 women of European ancestry with metastatic breast cancer, 606 of whom died of breast cancer. We identified two germline variants on chromosome 1, rs138569520 and rs146023652, significantly associated with breast cancer-specific survival (P = 3.19 × 10−8 and 4.42 × 10−8). In silico analysis suggested a potential regulatory effect of the variants on the nearby target genes SDE2 and H3F3A. However, the variants showed no evidence of association in a smaller replication dataset. The validation dataset was obtained from the SNPs to Risk of Metastasis (StoRM) study and included 293 patients with metastatic primary breast cancer at diagnosis. Ultimately, larger replication studies are needed to confirm the identified associations.

Download Full-text

The m6A-related gene signature for predicting the prognosis of breast cancer

PeerJ ◽

10.7717/peerj.11561 ◽

2021 ◽

Vol 9 ◽

pp. e11561

Author(s):

Shanliang Zhong ◽

Zhenzhong Lin ◽

Huanwen Chen ◽

Ling Mao ◽

Jifeng Feng ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

High Risk ◽

Cancer Survival ◽

Risk Group ◽

Gene Signature ◽

Breast Cancer Survival ◽

Breast Cancer Patients ◽

Related Gene ◽

Rna Methylation

N6-methyladenosine (m6A) modification has been shown to participate in tumorigenesis and metastasis of human cancers. The present study aimed to investigate the roles of m6A RNA methylation regulators in breast cancer. We used LASSO regression to identify m6A-related gene signature predicting breast cancer survival with the datasets downloaded from Gene Expression Omnibus and The Cancer Genome Atlas (TCGA). RNA-Seq data of 3409 breast cancer patients from GSE96058 and 1097 from TCGA were used in present study. A 10 m6A-related gene signature associated with prognosis was identified from 22 m6A RNA methylation regulators. The signature divided patients into low- and high-risk group. High-risk patients had a worse prognosis than the low-risk group. Further analyses indicated that IGF2BP1 may be a key m6A RNA methylation regulator in breast cancer. Survival analysis showed that IGF2BP1 is an independent prognostic factor of breast cancer, and higher expression level of IGF2BP1 is associated with shorter overall survival of breast cancer patients. In conclusion, we identified a 10 m6A-related gene signature associated with overall survival of breast cancer. IGF2BP1 may be a key m6A RNA methylation regulator in breast cancer.

Download Full-text